Chicago—The standard of care for subgroups of patients with metastatic pancreatic, urothelial and hormone-sensitive prostate cancers, and recurrent uterine and ovarian carcinosarcoma have changed, according to data presented at the 2019 annual meeting of the American Society of Clinical Oncology. In each case, trials presented at the meeting provided support for new standards based on unprecedented disease control, usually involving improved overall survival (OS).
JULY 29, 2019